{"result": {"id": "chatcmpl-578", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "**Bevacizumab** is an anti-angiogenic drug that inhibits angiogenesis, the formation of new blood vessels, by targeting vascular endothelial growth factor (VEGF). It works by blocking VEGF, which plays a crucial role in angiogenesis. Bevacizumab is used to treat various conditions, including cancers like non-small cell lung cancer (NSCLC) and osteosarcoma, as well as eye diseases such as vascular leakage.  It can also be used for treating certain types of GI bleeding and CoNV, where it helps inhibit tumor growth. \n\nBevacizumab is classified as an antitumorigenic drug. It has potential applications in treating corneal neovascularization and other conditions. \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743288462, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 143, "prompt_tokens": 363, "total_tokens": 506, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"BEVACIZUMAB\"\nDescription List: [\"**Bevacizumab** is an anti-VEGF antibody classified as an anti-angiogenesis inhibitor.  It works by blocking vascular endothelial growth factor (VEGF), which plays a crucial role in angiogenesis, the formation of new blood vessels. This drug inhibits the growth of new blood vessels and has been used to treat various conditions, including non-small cell lung cancer (NSCLC) and osteosarcoma. Bevacizumab is also used in anti-angiogenic therapies targeting the VEGF pathway for treating cancers and certain eye diseases like vascular leakage. It has potential applications in treating corneal neovascularization and other conditions.  It is an antitumorigenic drug. \\n\", \"**Bevacizumab** is an anti-angiogenic drug used to treat various conditions, including certain cancers and eye conditions. It inhibits angiogenesis, the formation of new blood vessels, by targeting vascular endothelial growth factor (VEGF).  It is commonly prescribed for treating **CoNV**, a condition where it helps inhibit tumor growth. Bevacizumab can also be used to treat GI bleeding. \\n\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_f83643c3e520b5b4dd0e178b8eb5b3c3e0877ee29461bd690f6c91dc2e242ab2_v2"}